ReviewPathogens (Basel, Switzerland)2021
Human Babesiosis in Europe.
Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Tick-borne pathogens in dogs and their ticks in France: Molecular and serological evidence from a multicenter participatory study.One health (Amsterdam, Netherlands) · 2026Article
- Tick-Borne Pathogens in Wild Cervids from Poland: A Molecular Survey onAnimals : an open access journal from MDPI · 2026Article
- Molecular investigation of tick-borne pathogens in Ixodes ricinus feeding on lizards in the Central Pyrenees, Spain.Parasitology research · 2026Article
- Epidemiology of tick-borne diseases diagnosed in patients in north-eastern Italy, 2015-2022.BMC infectious diseases · 2026Observational
- Zoonotic Pathogens inPathogens (Basel, Switzerland) · 2026Article
- Babesiosis and Its Significance in Transfusion Medicine from a European Point of View.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Furamidine, a methyltransferase inhibitor, is a potential anti-Babesia spp. chemotherapeutic.Parasitology research · 2025Article
- A one-health approach to surveillance of tick-borne pathogens across different host groups.BMC veterinary research · 2025Article
- Human babesiosis: The past, present and future.Expert reviews in molecular medicine · 2025Review
- Human Babesiosis Caused by Babesia venatorum, Russia, 2024.Emerging infectious diseases · 2025Article
- Application of Multiplatform Mass Spectrometry to the Study ofInternational journal of molecular sciences · 2025Article
- Elucidating the functional role of the novel BdP50 protein and extracellular vesicles in the human erythrocyte infection by Babesia divergens.PLoS neglected tropical diseases · 2025Article
- Impact of Human Granulocytic Anaplasmosis in Spain from 1997 to 2022.Tropical medicine and infectious disease · 2025Review
- Epidemiological, Clinical and Analytical Features in Lyme Borreliosis Patients Seropositive forMicroorganisms · 2025Article
- Three Cases of Human Babesiosis, Italy, 2017-2020.Emerging infectious diseases · 2025Article
- Article
- Analysis of ticks (Acari: Ixodida) and associated microorganisms collected on the North Sea Island of Heligoland.Parasitology research · 2025Article
- Zoonotic Tick-Borne Pathogens in Ixodes ricinus Complex (Acari: Ixodidae) From Urban and Peri-Urban Areas of Kosovo.Zoonoses and public health · 2025Article
- Article
- Small mammals as hosts of vector-borne pathogens in the High Tatra Mountains region in Slovakia, Central Europe.Current research in parasitology & vector-borne diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Babesiosis is attracting increasing attention as a worldwide emerging zoonosis. The first case of human babesiosis in Europe was described in the late 1950s and since then more than 60 cases have been reported in Europe. While the disease is relatively rare in Europe, it is significant because the majority of cases present as life-threatening fulminant infections, mainly in immunocompromised patients. Although appearing clinically similar to human babesiosis elsewhere, particularly in the USA, most European forms of the disease are distinct entities, especially concerning epidemiology, human susceptibility to infection and clinical management. This paper describes the history of the disease and reviews all published cases that have occurred in Europe with regard to the identity and genetic characteristics of the etiological agents, pathogenesis, aspects of epidemiology including the eco-epidemiology of the vectors, the clinical courses of infection, diagnostic tools and clinical management and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.